VOL: 101, ISSUE: 25, PAGE NO: 31
- Seretide: Evohaler 50; 125; 250.
- Seretide: Accuhaler 100; 250; 500.
- Symbicort Turbohaler 100/6; 200/6 400/12.
- This inhaler contains two active ingredients: inhaled corticosteroids, either fluticasone propionate or budesonide; and a long-acting beta2 agonist, which is either salmeterol or formoterol fumarate.
- The inhaled corticosteroids act to decrease inflammation in airways.
- The long-acting beta2 agonist causes brochodilation.
- Respiratory system drugs.
- Used in the treatment of asthma and chronic obstructive pulmonary disease.
- Known sensitivity or allergy to any ingredient.
- Active tuberculosis.
- Cardiovascular disease.
- Candidiasis of mouth or throat.
- Muscle cramps.
- Sleep disturbance.
- High doses have the potential to cause adrenal suppression.
- Small increased risk of glaucoma with prolonged use at high dosage.
- Potential for hypokalaemia can be increased by theophylline corticosteroids and diuretics.
- Metered dose aerosol inhaler.
- Metered dose dry powder inhaler.
- The use of long-acting reliever/preventer inhalers should be informed by evidence-based guidelines such as those produced by SIGN (2004) and NICE (2004).
- Assess respiratory function.
- Assess ability to use the inhaler device and reassess technique at regular appointments, giving coaching where appropriate.
- No significant growth retardation has been noted. However, it is recommended that the height of all children on regular therapy is monitored.
- Ensure the patient can self-manage appropriately.
- Advise patients not to stop this medication without speaking to the prescribing health care professional.
- Give smoking cessation advice if appropriate.
- Ensure patients know never to use this medication to treat an acute attack. They should have an appropriate short-acting reliever inhaler for this purpose.
- Give appropriate advice about maintaining the device.
Nurses should refer to manufacturer’s summary of product characteristics and to appropriate local guidelines